Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events.
Tim Jang, Maria Poplawska, Emanuela Cimpeanu...
https://pubmed.ncbi.nlm.nih.gov/34544432/Actively Recruiting
Led by University of Maryland, Baltimore · Updated on 2025-12-24
30
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are evaluating the use of virtual reality devices as an addition to standard care for adults with sickle cell disease who are experiencing painful vaso-occlusive crises. This trial aims to compare different types of virtual reality experiences with a placebo control to understand their impact on pain and other treatment outcomes during these acute pain episodes. Participants will be randomly assigned to one of three groups an active immersive virtual reality group where patients can interact with the environment using a headset and hand-held controllers a passive immersive virtual reality group where patients view but do not interact with the virtual environment or a placebo group using blindfolds and ear plugs. Each intervention lasts up to two hours during the emergency department visit. During the study, participants will be assessed at four timepoints before, during, and after the intervention to rate their pain and report changes in pain levels. Researchers will also collect data on device comfort, hospital admission rates, opioid use, and treatment duration. Patients will complete questionnaires about their experience with the intervention. The primary outcome is the change in pain scores one hour after completing the intervention.
CONDITIONS
Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
R
R. Gentry Wilkerson, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Maryland, Baltimore
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Active VR as Adjunct | Passive VR as Adjunct | Placebo Comparator as Adjunct |
|---|---|---|---|
| What it is | Participants use an immersive virtual reality headset and interactive controllers as an addition to their usual opioid-based pain management to immerse in a digital environment during acute pain crisis. | Participants use a virtual reality headset displaying passive content, with limited or no interaction, as an addition to their usual opioid-based pain treatment for acute crisis. | Participants wear a blindfold and use ear plugs to simulate sensory deprivation, in addition to their usual care, to serve as a placebo comparator for pain management. |
| Role in the trial | Investigational intervention; tested for its effect on pain and comfort as an adjunct to standard treatment during ED management. | Investigational intervention; tested to assess whether non-interactive virtual content provides similar benefit as active immersive VR. | Trial placebo comparator designed to control for the sensory and attention effects apart from active/passive VR activity. |
| Primary use | Explored for its potential to reduce acute pain and improve comfort for adults with sickle cell crisis when combined with usual pain treatment. | Assessed to determine whether passively viewed virtual content helps with pain or comfort for acute pain episodes in sickle cell disease. | Used to control for non-specific effects such as interaction with study staff, expectation, and sensory input. |
| How it is given or performed | Participants wear a virtual reality headset and use interactive controllers, engaging actively with digital environments during their emergency department stay. | Participants wear a virtual reality headset, viewing non-interactive visual content only, with no use of controllers. | Participants wear a blindfold and ear plugs to block visual and auditory input, mimicking some aspects of VR use without digital content. |
| Evidence status | Previous studies of VR in pain management have shown reductions in acute pain in general inpatient settings. Systematic review evidence suggests VR may help manage pain and anxiety, but definitive benefit specifically for sickle cell crisis is not yet established. | There is limited published data directly comparing passive to active VR use for acute pain. General evidence for VR supports interactive experiences; effect of passive viewing is less studied. | No therapeutic effect is expected from the sensory deprivation placebo. This arm is used to control for the non-specific effects of device use. |
| Important limitations | Effectiveness and comfort are being investigated specifically for sickle cell crisis; device tolerance may vary and results may not generalize to all patients or settings. | Clinical benefit of passive VR is less understood, and patient engagement or distraction effects may be reduced compared to interactive VR. | This comparator does not represent usual pain care outside the trial and has no expected therapeutic effect. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 hours during emergency department visit
Participants receive either active or passive virtual reality interventions or a placebo (blindfold and ear plugs) as an adjunct to usual care for vaso-occlusive crises. The intervention lasts up to 2 hours with pain and comfort assessments conducted before, during, and after the intervention.
1 treatment session with 4 assessments
Duration - Day of enrollment
Participants complete a questionnaire about their experience with the intervention and data on hospital disposition and opioid use are collected on the day of enrollment.
1 follow-up assessment (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Tim Jang, Maria Poplawska, Emanuela Cimpeanu...
https://pubmed.ncbi.nlm.nih.gov/34544432/Ifeyinwa Osunkwo, Deepa Manwani, Julie Kanter
https://pubmed.ncbi.nlm.nih.gov/33062233/Hants Williams, Paula Tanabe
https://pubmed.ncbi.nlm.nih.gov/26596876/Prithu Sundd, Mark T Gladwin, Enrico M Novelli
https://pubmed.ncbi.nlm.nih.gov/30332562/A Chuan, J J Zhou, R M Hou...
https://pubmed.ncbi.nlm.nih.gov/32720308/Yves Duroseau, David Beenhouwer, Michael S Broder...
https://pubmed.ncbi.nlm.nih.gov/34401866/Anurag K Agrawal, Simon Robertson, Liat Litwin...
https://pubmed.ncbi.nlm.nih.gov/30362236/Stephanie Harris Mercado
https://pubmed.ncbi.nlm.nih.gov/36752670/Vinayak Smith, Ritesh Rikain Warty, Joel Arun Sursas...
https://pubmed.ncbi.nlm.nih.gov/33136055/University of Maryland, Baltimore
Lead Sponsor